S. 1041Introduced
Affordable Prescriptions for Patients Act
Limits the patents a biologic drug maker may assert in certain biosimilar patent lawsuits under the FDA approval framework, with court authority to expand that limit
Plain-English overview
What this bill does
Limits the patents a biologic drug maker may assert in certain biosimilar patent lawsuits under the FDA approval framework, with court authority to expand that limit
Key points
- Limit asserted biologic patents
- Allow court increases
Current status
Where it stands
Status
Introduced
Latest action
2025-04-10 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.
Related context
Topics and policy areas
undefinedAdministrative remediesCivil actions and liabilityCommerceCompetition and antitrustConsumer affairsDrug safety, medical device, and laboratory regulationFederal Trade Commission (FTC)